U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Reishi D. International, Inc. - 537352 - 11/27/2018
  1. Warning Letters

CLOSEOUT LETTER

Reishi D. International, Inc. MARCS-CMS 537352 —

Product:
Dietary Supplements
Recipient:
Recipient Name
Zheng Xiong Li
Recipient Title
CEO
Reishi D. International, Inc.

451 Victory Ave
Suite 3
South San Francisco, CA 94080
United States

Issuing Office:
Office Human and Animal Foods Division West 5

1431 Harbor Bay Parkway
Alameda, CA 94502-7070
United States

Dear Mr. Zheng Xiong Li:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS # 537352), dated February 06, 2018. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Robert B. Mcnab
for/
Sergio Chavez, Director of Compliance
Office Human and Animal Foods
Division West 5

Back to Top